academic journalism

Advanced Echocardiography Findings of HER2-Positive Breast Cancer Patients Following Anthracycline-Based Chemotherapy

AUTHORS

avatar Azin Alizadehasl ORCID 1 , avatar Mehrdad Haghazali ORCID 2 , avatar Hamed Bazrafshan Drissi ORCID 3 , avatar Amir Askarinejad ORCID 2 , avatar Seyed Amirhossein Emami ORCID 4 , avatar Seyed Asadollah Mousavi 4 , avatar Mohammad Vaezi ORCID 5 , avatar Kamran Roudini ORCID 6 , avatar Robab Anbiaie ORCID 7 , avatar Payam Azadeh 7 , avatar Maedeh Barahman ORCID 7 , avatar Feridoun Noohi 8 , avatar Maryam Yazdani ORCID 1 , *

1 Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran

2 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran

3 Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, IR Iran

4 Department of Hematology-Oncology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IR Iran

5 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IR Iran

6 Department of Internal Medicine, School of Medicine Cancer Research Center Imam Khomeini Hospital Tehran University of Medical Sciences, Tehran, IR Iran

7 Department of Radiation Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

8 Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran

How to Cite: Alizadehasl A, Haghazali M, Bazrafshan Drissi H, Askarinejad A, Emami S A , et al. Advanced Echocardiography Findings of HER2-Positive Breast Cancer Patients Following Anthracycline-Based Chemotherapy. Int Cardio Res J. 2022;16(3):e128445.

ARTICLE INFORMATION

International Cardiovascular Research Journal: 16 (3); e128445
Published Online: September 30, 2022
Article Type: Research Article
Received: May 23, 2022
Revised: July 31, 2022
Accepted: November 16, 2022
READ FULL TEXT

Abstract

Background: Cardiotoxicity, a common complication of chemotherapy, may have
irreversible adverse effects on the heart. Anthracycline-based chemotherapy for breast
cancer can lead to dilation-hypokinetic cardiomyopathy, eventuating in heart failure.
As the primary diagnostic tool for cardiovascular toxicity, echocardiography may be
essential in evaluating the heart function of such patients.
Objectives: This study aimed to identify the most important echocardiography findings
for proper and timely diagnosis of cardiotoxicity in patients with HER2-positive breast
cancer undergoing anthracycline-based chemotherapy.
Methods: Our final analysis included 132 female patients who were HER2-positive and
had breast cancer. All of these patients had one pre-chemotherapy echocardiography and
at least one echocardiography after three episodes of anthracycline-based chemotherapy.
The patients’ age, body mass index, and history of chemotherapy were recorded. Mean
alterations from baseline echocardiography to echocardiography after three episodes of
chemotherapy were calculated for all parameters evaluated. Data analysis was conducted
using the Statistical Package for the Social Sciences v. 26.
Results: Significant changes were seen in three-dimensional left ventricular ejection
fraction (LVEF 3D), two-dimensional left ventricular ejection fraction (LVEF 2D), left
ventricular global circumferential strain (LVGCS), left ventricular global longitudinal
strain (LVGLS), left ventricular end-diastolic volume (LVEDV), stroke volume (SV),
left ventricular end-systolic volume (LVESV), right ventricular end-systolic dimension
(RVESD) in patients with breast cancer (P < 0.0001). RVESD, LVESV, LVEDV, and
SV significantly increased after three chemotherapy episodes, but LVEF (3D and 2D),
absolute LVGCS, and absolute LVGLS fell significantly.
Conclusion: LVEF (3D and 2D), LVGCS, LVGLS, LVEDV, LVESV, SV, and RVESD are
important echocardiography parameters in diagnosing cardiotoxicity in patients with
HER2-positive breast cancer.

Fulltext

The full-text is available in pdf.

References

  • 1.

    The references are available in pdf.

© 2022, Shiraz University of Medical Sciences.
COMMENTS

LEAVE A COMMENT HERE: